Mario Negri Institute for Pharmacological Research Clinical Trials
Sponsors / Mario Negri Institute for Pharmacological Research
Mario Negri Institute for Pharmacological Research appears as lead sponsor on 104 trial records in ClinicalTrials.gov. The portfolio currently includes 15 recruiting studies, 15 active non-recruiting studies, and 40 completed studies. 17 trials in this portfolio were terminated or withdrawn before completion. The most common reasons cited for termination include slow or insufficient recruitment, safety concerns. Cumulative planned enrollment across all listed trials is 351,145 participants. These counts reflect the current state of the public ClinicalTrials.gov registry.
104
Total Trials
15
Recruiting
15
Other Active
40
Completed
17
Terminated / Withdrawn
351,145
Total Enrollment
Termination reasons: Other53% · Recruitment35% · Safety12%
Recent Terminations
- Breast Neoplasm Female"Low enrolment rate"
- Hyperkalemia"Unable to reach planned study sample size due to increased patient failure to meet inclusion criteria."
- Fallopian Tube Cancer"Low accrual rate"
- Lung Cancer"Novartis has decided to terminate the trial due to the recent results made available from the Novartis CANOPY A study (CACZ885T2301), this decision is not related to any safety data for Canakinumab"
- Open Angle Glaucoma"low accrual"
- Rheumatoid Arthritis"Slow recrutiment"
- COVID-19"interrupted early due to the drastic reduction in the number of cases"
- Diabetes Mellitus, Type 2"Insulin-HF study was prematurely ended due principally to low recruitment rate."
- Triple Negative Breast Cancer"Low accrual rate"
- Renal Cell Carcinoma"Stopped on November 16th 2016, because of recruitment failure."
Active Trials (15 total)
- NCT07331103
- NCT06680050
- NCT05805202
- NCT06594367
- NCT05482945
- NCT04095156
- NCT06193616
- NCT06884410
- NCT07016282
- NCT06242327
- NCT06841887
- Healthy NANCT05985122
- NCT06334692
- NCT06354829
- NCT06374095
- NCT06411353
- NCT06797609
- NCT06858280
- NCT06994468
- NCT04905264
Top Conditions
Membranous nephropathy (6) Autosomal dominant polycystic kidney disease (adpkd) (5) Appropriateness (3) COVID-19 (3) Kidney transplant (3) Nephrotic syndrome (3) Atypical hemolytic uremic syndrome (2) Autosomal dominant polycystic kidney (2) Autosomal dominant polycystic kidney disease (2) COVID-19 (2)